Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - BIOLASE, INC | c15233e8vk.htm |
| EX-99.2 - EXHIBIT 99.2 - BIOLASE, INC | c15233exv99w2.htm |
Exhibit 99.1
NEWS RELEASE for April 6, 2011
BIOLASE ANNOUNCES THAT IT EXPECTS REVENUES FOR FIRST QUARTER TO
EXCEED PREVIOUS GUIDANCE
EXCEED PREVIOUS GUIDANCE
Net Revenue Expected to Total Approximately $10.4 Million,
an Increase of 136 Percent over Q1, 2010
an Increase of 136 Percent over Q1, 2010
IRVINE, CA (April 6, 2011) — BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental
laser manufacturer and distributor, announced today that, based on a preliminary review of its
financial performance, the Company expects to report net revenue of approximately $10.4 million for
the first quarter ended March 31, 2011. This is an increase of approximately 10 percent from the
updated guidance provided last month in the mid-range of $9.5 million ($9.25 million to $9.75
million) and an increase of approximately 136 percent from $4.4 million of net revenue for the
first quarter ended March 31, 2010.
Federico Pignatelli, Chairman and CEO, said, “We are pleased with the better than expected revenues
that we believe we have achieved during the first quarter, traditionally our slowest quarter of the
year. Our recently expanded direct sales force in North America and several of our international
distributors have contributed to the growing sales traction in the period and a strong initial
demand for our new flagship all-tissue laser system launched in January, the WaterLase® iPlus™,
have all contributed to the quarter performance. Orders for the WaterLase iPlus have exceeded our
expectations, and we are working diligently to manufacture enough to keep up with the current
demand. The launch of the Waterlase iPlus is shaping up to become the most successful in the
history of the Company and we believe it will be a strong contributor to our future revenue growth.
Demand for our wireless iLase™ five watt diode laser system also remained strong in the period as
we continued to receive new orders and work through our existing backlog.”
The Company will provide additional details on a quarterly conference call and webcast when it
reports full financial results in May.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World’s leading Dental Laser company, is a medical technology company
that develops, manufactures and markets dental lasers and also distributes and markets dental
imaging equipment, products that are focused on technologies that advance the practice of dentistry
and medicine. The Company’s laser products incorporate patented and patent pending technologies
designed to provide clinically superior performance with less pain and faster recovery times. Its
imaging products provide cutting-edge technology at competitive prices to deliver the best results
for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a
broad range of dental procedures, including cosmetic and complex surgical applications, and a full
line of dental imaging equipment. Other products under development address ophthalmology and other
medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at
http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and
YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor
provided by the Securities Reform Act of 1995 that are based on the current expectations and
estimates by our management. These forward-looking statements can be identified through the use of
words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,”
“may,” “will,” and variations of these words or similar expressions. Forward-looking statements are
based on management’s current, preliminary expectations and are subject to risks, uncertainties and
other factors which may cause the Company’s actual results to differ materially from the statements
contained herein, and are described in the Company’s reports it files with the Securities and
Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed
on forward-looking statements. Such information is subject to change, and we undertake no
obligation to update such statements.
For further information, please contact: Jill Bertotti, of Allen & Caron, +1-949-474-4300.
# # # #